Nature Communications (Oct 2022)
Breadth of SARS-CoV-2 neutralization and protection induced by a nanoparticle vaccine
- Dapeng Li,
- David R. Martinez,
- Alexandra Schäfer,
- Haiyan Chen,
- Maggie Barr,
- Laura L. Sutherland,
- Esther Lee,
- Robert Parks,
- Dieter Mielke,
- Whitney Edwards,
- Amanda Newman,
- Kevin W. Bock,
- Mahnaz Minai,
- Bianca M. Nagata,
- Matthew Gagne,
- Daniel C. Douek,
- C. Todd DeMarco,
- Thomas N. Denny,
- Thomas H. Oguin,
- Alecia Brown,
- Wes Rountree,
- Yunfei Wang,
- Katayoun Mansouri,
- Robert J. Edwards,
- Guido Ferrari,
- Gregory D. Sempowski,
- Amanda Eaton,
- Juanjie Tang,
- Derek W. Cain,
- Sampa Santra,
- Norbert Pardi,
- Drew Weissman,
- Mark A. Tomai,
- Christopher B. Fox,
- Ian N. Moore,
- Hanne Andersen,
- Mark G. Lewis,
- Hana Golding,
- Robert Seder,
- Surender Khurana,
- Ralph S. Baric,
- David C. Montefiori,
- Kevin O. Saunders,
- Barton F. Haynes
Affiliations
- Dapeng Li
- Duke Human Vaccine Institute, Duke University School of Medicine
- David R. Martinez
- Department of Epidemiology, University of North Carolina at Chapel Hill
- Alexandra Schäfer
- Department of Epidemiology, University of North Carolina at Chapel Hill
- Haiyan Chen
- Duke Human Vaccine Institute, Duke University School of Medicine
- Maggie Barr
- Duke Human Vaccine Institute, Duke University School of Medicine
- Laura L. Sutherland
- Duke Human Vaccine Institute, Duke University School of Medicine
- Esther Lee
- Duke Human Vaccine Institute, Duke University School of Medicine
- Robert Parks
- Duke Human Vaccine Institute, Duke University School of Medicine
- Dieter Mielke
- Department of Surgery, Duke University School of Medicine
- Whitney Edwards
- Duke Human Vaccine Institute, Duke University School of Medicine
- Amanda Newman
- Duke Human Vaccine Institute, Duke University School of Medicine
- Kevin W. Bock
- Infectious Disease Pathogenesis Section, Comparative Medicine Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Mahnaz Minai
- Infectious Disease Pathogenesis Section, Comparative Medicine Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Bianca M. Nagata
- Infectious Disease Pathogenesis Section, Comparative Medicine Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Matthew Gagne
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Daniel C. Douek
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- C. Todd DeMarco
- Duke Human Vaccine Institute, Duke University School of Medicine
- Thomas N. Denny
- Duke Human Vaccine Institute, Duke University School of Medicine
- Thomas H. Oguin
- Duke Human Vaccine Institute, Duke University School of Medicine
- Alecia Brown
- Duke Human Vaccine Institute, Duke University School of Medicine
- Wes Rountree
- Duke Human Vaccine Institute, Duke University School of Medicine
- Yunfei Wang
- Duke Human Vaccine Institute, Duke University School of Medicine
- Katayoun Mansouri
- Duke Human Vaccine Institute, Duke University School of Medicine
- Robert J. Edwards
- Duke Human Vaccine Institute, Duke University School of Medicine
- Guido Ferrari
- Duke Human Vaccine Institute, Duke University School of Medicine
- Gregory D. Sempowski
- Duke Human Vaccine Institute, Duke University School of Medicine
- Amanda Eaton
- Duke Human Vaccine Institute, Duke University School of Medicine
- Juanjie Tang
- Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration
- Derek W. Cain
- Duke Human Vaccine Institute, Duke University School of Medicine
- Sampa Santra
- Beth Israel Deaconess Medical Center
- Norbert Pardi
- Department of Microbiology, University of Pennsylvania
- Drew Weissman
- Department of Medicine, University of Pennsylvania
- Mark A. Tomai
- Corporate Research Materials Lab, 3M Company
- Christopher B. Fox
- Infectious Disease Research Institute
- Ian N. Moore
- Infectious Disease Pathogenesis Section, Comparative Medicine Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Hanne Andersen
- BIOQUAL
- Mark G. Lewis
- BIOQUAL
- Hana Golding
- Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration
- Robert Seder
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Surender Khurana
- Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration
- Ralph S. Baric
- Department of Epidemiology, University of North Carolina at Chapel Hill
- David C. Montefiori
- Duke Human Vaccine Institute, Duke University School of Medicine
- Kevin O. Saunders
- Duke Human Vaccine Institute, Duke University School of Medicine
- Barton F. Haynes
- Duke Human Vaccine Institute, Duke University School of Medicine
- DOI
- https://doi.org/10.1038/s41467-022-33985-4
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 15
Abstract
The authors have previously demonstrated the neutralising capacity of their nanoparticle vaccine, as well as showing protection of non-human primates from SARS-CoV-2 WA-1 infection. In this work, they investigate the ability of their vaccine candidate to neutralise SARS-CoV-2 variants of concern, and protect animals from other sarbecoviruses.
